Search - tctmd.com

Displaying 1 - 20 of 41

Sort: Relevancy | Date

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Conference News TCT 2024

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

Michael O'Riordan

October 29, 2024

News Conference News ACC 2023

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Caitlin E. Cox

March 14, 2023

News Daily News

Tocilizumab Improves Myocardial Salvage After STEMI: ASSAIL-MI

Michael O'Riordan

April 12, 2021

News Conference News ESC 2020

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

Caitlin E. Cox

August 31, 2020

News Daily News

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

Yael L. Maxwell

December 20, 2019

News Conference News AHA 2019

No Benefit of Colchicine in All-Comers PCI

Shelley Wood

November 17, 2019

COLCOT Renews Hope for Anti-inflammatory Secondary Prevention

News Conference News AHA 2019

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

Caitlin E. Cox

November 16, 2019

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Shelley Wood

November 11, 2019

News Daily News

Recurrent Events Common Among Young Patients With CAD

Michael O'Riordan

October 11, 2019

News Daily News

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Yael L. Maxwell

May 15, 2019

News Daily News

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

Michael O'Riordan

March 08, 2019

News Daily News

TCTMD’s Top 10 Most Popular Stories for February 2019

Shelley Wood

March 01, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Conference News AHA 2018

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Caitlin E. Cox

November 13, 2018

News Conference News AHA 2018

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

Michael O'Riordan

November 10, 2018

News Conference News AHA 2018

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

Shelley Wood

November 05, 2018

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

News Daily News

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

Caitlin E. Cox

October 31, 2018

Advertisement

ACC: It’s Time for Clinicians to Address Inflammation in CVD

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Colchicine Surprise: No Help Post-MI, Large CLEAR SYNERGY Trial Shows

CRP More Predictive of Future Events Than LDL in Statin-Treated Patients

Tocilizumab Improves Myocardial Salvage After STEMI: ASSAIL-MI

LoDoCo2: Colchicine Protective in Large RCT of Chronic Coronary Disease

Year in Review: New Guidelines, Inclisiran, Dapagliflozin Impact CVD Prevention in 2019

No Benefit of Colchicine in All-Comers PCI

COLCOT Renews Hope for Anti-inflammatory in Secondary Prevention: Colchicine

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

Recurrent Events Common Among Young Patients With CAD

Residual Inflammatory Risk and PCI: Worthy Biomarker or Merely Something Else to Measure?

Rising Inflammatory Tides: Increasing CRP Levels After ACS Tied to Greater CVD Risks

TCTMD’s Top 10 Most Popular Stories for February 2019

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Canakinumab Reduces Heart-Failure Hospitalizations Among Responders: CANTOS Subanalysis

Methotrexate, an Anti-inflammatory, Fails to Lower Risk of Cardiovascular Events: CIRT

AHA 2018: New Cholesterol Guidelines, Fish Oil, Diabetes Meds, and Inflammation Blow Into the Windy City

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Lingering Signs of Inflammation Post-PCI Signal More Death, MI at 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content